Many sterile injectable products begin in a vial before transitioning to a prefilled syringe as clinical development progresses or commercial strategies evolve. Because our Aston filling line supports both vial and syringe filling, your team can manufacture in the format that best fits your program today while reducing the complexity of transitioning to a different container closure system in the future.

When you’re ready, we help guide syringe component selection, process development, and the technical transfer from vial to prefilled syringe, all within the same manufacturing environment whenever possible. This approach helps minimize risk, avoid unnecessary technology transfers between organizations, and keep your program moving toward commercialization.

Losing product during syringe filling can delay studies, reduce available doses, and increase development costs. At Argonaut, every milliliter matters.

That is why we designed our syringe filling processes to maximize yield. Our Aston filling line combines high-precision peristaltic filling, 100% non-destructive weight verification, and rescue dosing to minimize product loss while maintaining exceptional filling accuracy. Our Aston line can reduce line loss to as little as 100 mL when operating all four filling heads or 25 mL in single-head mode (excluding sterile filtration and PUPSIT), helping preserve valuable drug product in every batch.

We maximize your drug product yield through:

These advantages deliver meaningful impact on yield and overall manufacturing efficiency, especially for high-value biologics, oligonucleotides, vaccines, and other complex products.

Syringe filling is performed in a fully automated, isolator-based filling line designed to meet current regulatory expectations, including FDA and EU Annex 1 requirements. We also support PUPSIT on our Aston filling line.

Our team brings decades of aseptic manufacturing and quality experience to help sponsors manage risk and navigate evolving requirements for sterile injectable products.

No two fill-finish programs are the same.

We help you develop a manufacturing strategy that reflects the unique needs of your formulation, syringe configuration, and development timeline. Our experience with complex formulations, including LNPs and biologics, helps inform strategies that account for formulation-specific processing requirements, product quality, and yield. Whether supporting an early clinical study, a commercial launch, or preparing for future combination product development, you will receive a practical, science-driven approach tailored to your project.

Sterile syringe filling is only one step in bringing a combination product or injectable therapy to market. Through our strategic partner network, we can simplify your manufacturing pipeline with integrated proposals and coordinated project management from API manufacturing through device assembly and final distribution.